Market research
TRVN Trevena Inc
PINK USD Healthcare
Latest close
As of 16 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 431
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- -1.95
Profile
Instrument facts
- Exchange
- PINK
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 431
- P/E ratio
- Not available
- Analyst target
- 5
- Dividend yield
- Not available
- Beta
- -1.95
About
About Trevena Inc
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Research context
Trevena Inc appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the TRVN discussion.
5 years, 6 months ago
Trevena, Inc is currently in a long term downtrend where the price is trading 26.1% below its 200 day moving average.
From a valuation standpoint, the stock is 94.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 78.2.
Trevena, Inc's total revenue rose by 122.6% to $69K since the same quarter in the previous year.
Its net income has dropped by 84.2% to $-12M since the same quarter in the previous year.
Finally, its free cash flow fell by 5.2% to $-7M since the same quarter in the previous year.
Based on the above factors, Trevena, Inc gets an overall score of 2/5.